The influx/efflux mechanisms of D-peptide ligand of nAChRs across the blood-brain barrier and its therapeutic value in treating glioma
Bing Han,Weiyi Xie,Yanxia Zhang,Shilin Zhou,Jiahong Yang,Ruifeng Wang,Yuqing Sun,Xiaoyi Wang,Jie Xu,Dawei Chen,Yinhang Wang,Jiasheng Lu,Fengling Ning,Fuming Shen,Min Liu,Hui Cai,Hong Xin,Weiyue Lu,Xuemei Zhang
DOI: https://doi.org/10.1016/j.jconrel.2020.08.010
IF: 11.467
2020-01-01
Journal of Controlled Release
Abstract:A D-peptide ligand of the nicotine acetylcholine receptors (nAChRs), termed (CDX)-C-D, enables drug delivery to the brain when incorporated into liposomes and has shown promise as a nanocarrier for treating brain diseases. However, few reports have described the mechanisms whereby (CDX)-C-D-modified liposomes traverse the blood-brain barrier (BBB). Here, we studied the molecular mechanisms enabling (CDX)-C-D (and its associated liposomes) to cross an in vitro BBB using a simulated cerebral endothelium monolayer formed by brain capillary endothelial cells (bEnd.3 cells). We also examined the mechanisms whereby (CDX)-C-D-modified liposomes cross the BBB in vivo using the brain efflux-index method. Transport of (CDX)-C-D and its modified liposomes was dominantly mediated via the lipid raft/caveolae endocytic pathway. Both the endoplasmic reticulum (ER) and Golgi complex participated in delivering (CDX)-C-D-modified liposomes to the plasma membrane (PM). (CDX)-C-D-modified liposomes also participated in the endosome/lysosome pathway (with high-efficiency BBB crossing observed in vitro), while competing for the ER/Golgi/PM pathway. In addition, nAChR alpha 7 did not promote the transportation of (CDX)-C-D-modified liposomes in vivo or in vitro, as assessed with alpha 7-knockout mice and by performing alpha-bungarotoxin (alpha-Bgt) binding-competition experiments. P-glycoprotein (P-gp) was identified as the main efflux transporter across the BBB, in vivo and in vitro. Using a xenograft nude mouse model of human glioblastoma multiforme, blocking the efflux function of P-gp with verapamil enhanced the therapeutic efficiency of (CDX)-C-D-modified liposomes that were formulated with doxorubicin against glioblastoma. The findings of this study reveal novel mechanisms underlying crossing of the BBB by (CDX)-C-D-modified liposomes, suggesting that (CDX)-C-D-modified liposomes can potentially serve as a powerful therapeutic tool for treating glioma.